Epoxyeicosatrienoic acids and soluble epoxide hydrolase: Potential therapeutic targets for inflammation and its induced carcinogenesis

American Journal of Translational Research

Volumn 2, Issue 4, 2010, Pages 447-457

  Norwood, Stephanie ^a   Liao, Jie ^a   Hammock, Bruce D ^b   Yang, Guang Yu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Carcinogenesis; Dihydroxyeicosatrienoic acids (DHETs); Epoxyeicosatrienoic acids (EETs); Inflammation; Non steroidal anti inflammatory drugs (NSAIDs); Soluble epoxide hydrolase (sEH); Therapy

Indexed keywords

12 (3 ADAMANTYL UREIDO)DODECANOIC ACID; 12 (3 ADAMANTYL UREIDO)DODECANOIC ACID N BUTYL ESTER; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROXYICOSATRIENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSANOID; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUKOTRIENE; LIPOXYGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SOLUBLE EPOXIDE HYDROLASE; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADENOMATOUS POLYP; ANTIINFLAMMATORY ACTIVITY; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLITIS; COLON CARCINOGENESIS; COLON ULCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG FATALITY; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MOUSE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RODENT; STROKE; ULCER COLITIS INDUCED CARCINOMA; ULCER COLITIS INDUCED DYSPLASIA; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL BLEEDING;

EID: 77957374067     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL and Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007; 82: 42-49.
2. Fretland AJ and Omiecinski CJ. Epoxide hydrolases: biochemistry and molecular biology. Chemico-Biological Interactions 2000; 129: 41-59.
3. Sandberg M and Meijer J. Structural characterization of the human soluble epoxide hydrolase gene (EPHX2). Biochem Biophys Res Commun 1996; 221: 333-339.
4. Larsson C, White I, Johansson C, Stark A and Meijer J. Localization of the human soluble epoxide hydrolase gene (EPHX2) to chromosomal region 8p21-p12. Hum Genet 1995; 95: 356-358.
5. Cronin A, Mowbray S, Durk H, Homburg S, Fleming I, Fisslthaler B, Oesch F and Arand M. The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc Natl Acad Sci U S A 2003; 100: 1552-1557.
6. Newman JW, Morisseau C, Harris TR and Hammock BD. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A 2003; 100: 1558-1563.
7. Argiriadi MA, Morisseau C, Hammock BD and Christianson DW. Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase. Proc Natl Acad Sci U S A 1999; 96: 10637-10642.
8. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC and Kroetz DL. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Molecular Pharmacology 2000; 57: 1011-1020.
9. Fang X, VanRollins M, Kaduce TL and Spector AA. Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells. Journal of Lipid Research 1995; 36: 1236-1246.
10. Johansson C, Stark A, Sandberg M, Ek B, Rask L and Meijer J. Tissue specific basal expression of soluble murine epoxide hydrolase and effects of clofibrate on the mRNA levels in extrahepatic tissues and liver. Archives of Toxicology 1995; 70: 61-63.
11. VanRollins M, Kaduce TL, Knapp HR and Spector AA. 14,15-Epoxyeicosatrienoic acid metabolism in endothelial cells. Journal of Lipid Research 1993; 34: 1931-1942.
12. Hollinshead M and Meijer J. Immunocytochemical analysis of soluble epoxide hydrolase and catalase in mouse and rat hepatocytes demonstrates a peroxisomal localization before and after clofibrate treatment. European Journal of Cell Biology 1988; 46: 394-402.
13. Eriksson AM, Zetterqvist MA, Lundgren B, Andersson K, Beije B and DePierre JW. Studies on the intracellular distributions of soluble epoxide hydrolase and of catalase by digitoninpermeabilization of hepatocytes isolated from control and clofibrate-treated mice. European Journal of Biochemistry 1991; 198: 471-476.
14. Mullen RT, Trelease RN, Duerk H, Arand M, Hammock BD, Oesch F and Grant DF. Differential subcellular localization of endogenous and transfected soluble epoxide hydrolase in mammalian cells: evidence for isozyme variants. FEBS Letters 1999; 445: 301-305.
15. Enayetallah AE, French RA, Barber M and Grant DF. Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J Histochem Cytochem 2006; 54: 329-335.
16. Capdevila JH, Falck JR and Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. Journal of Lipid Research 2000; 41: 163-181.
17. Capdevila JH and Falck JR. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochemical & Biophysical Research Communications 2001; 285: 571-576.
18. Karara A, Dishman E, Falck JR and Capdevila JH. Endogenous epoxyeicosatrienoylphospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. Journal of Biological Chemistry 1991; 266: 7561-7569.
19. Karara A, Dishman E, Jacobson H, Falck JR and Capdevila JH. Arachidonic acid epoxygenase. Stereochemical analysis of the endogenous epoxyeicosatrienoic acids of human kidney cortex. FEBS Letters 1990; 268: 227-230.
20. Karara A, Wei S, Spady D, Swift L, Capdevila JH and Falck JR. Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochemical & Biophysical Research Communications 1992; 182: 1320-1325.
21. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P and Spector AA. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. American Journal of Physiology 1999; 277: H2098-2108.
22. Roman RJ and Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiological Reviews 2002; 82: 131-185.
23. Spector AA, Fang X, Snyder GD, Weintraub NL, Spector AA, Fang X, Snyder GD and Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Progress in Lipid Research 2004; 43: 55-90.
24. Li PL and Campbell WB. Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circulation Research 1997; 80: 877-884.
25. Fukao M, Mason HS, Kenyon JL, Horowitz B and Keef KD. Regulation of BK(Ca) channels expressed in human embryonic kidney 293 cells by epoxyeicosatrienoic acid. Molecular Pharmacology 2001; 59: 16-23.
26. Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC and Liao JK. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. Journal of Biological Chemistry 2001; 276: 15983-15989.
27. Chen JK, Capdevila J and Harris RC. Overexpression of C-terminal Src kinase blocks 14, 15-epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis. Journal of Biological Chemistry 2000; 275: 13789-13792.
28. Hoebel BG and Graier WF. 11,12-Epoxyeicosatrienoic acid stimulates tyrosine kinase activity in porcine aortic endothelial cells. European Journal of Pharmacology 1998; 346: 115-117.
29. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, Rockman HA, Hammock BD, Murphy E, Zeldin DC, Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, Rockman HA, Hammock BD, Murphy E and Zeldin DC. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATPsensitive K+ channels and p42/p44 MAPK pathway.[see comment]. Circulation Research 2004; 95: 506-514.
30. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, Zeldin DC, Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW and Zeldin DC. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. Journal of Pharmacology & Experimental Therapeutics 2005; 314: 522-532.
31. Fang X, Kaduce TL, VanRollins M, Weintraub NL and Spector AA. Conversion of epoxyeicosatrienoic acids (EETs) to chain-shortened epoxy fatty acids by human skin fibroblasts. Journal of Lipid Research 2000; 41: 66-74.
32. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD and Spector AA. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. Journal of Biological Chemistry 2001; 276: 14867-14874.
33. Fang X, Kaduce TL, Weintraub NL, VanRollins M and Spector AA. Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circulation Research 1996; 79: 784-793.
34. Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, Capdevila JH, Cowart LA, Wei S, Hsu M-H, Johnson EF, Krishna MU, Falck JR and Capdevila JH. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. Journal of Biological Chemistry 2002; 277: 35105-35112.
35. Carroll MA, Balazy M, Margiotta P, Falck JR and McGiff JC. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. Journal of Biological Chemistry 1993; 268: 12260-12266.
36. Zhang JY, Prakash C, Yamashita K and Blair IA. Regiospecific and enantioselective metabolism of 8,9-epoxyeicosatrienoic acid by cyclooxygenase. Biochemical & Biophysical Research Communications 1992; 183: 138-143.
37. Pace-Asciak CR, Granstrom E and Samuelsson B. Arachidonic acid epoxides. Isolation and structure of two hydroxy epoxide intermediates in the formation of 8,11,12-and 10,11,12-trihydroxyeicosatrienoic acids. Journal of Biological Chemistry 1983; 258: 6835-6840.
38. Spearman ME, Prough RA, Estabrook RW, Falck JR, Manna S, Leibman KC, Murphy RC and Capdevila J. Novel glutathione conjugates formed from epoxyeicosatrienoic acids (EETs). Archives of Biochemistry & Biophysics 1985; 242: 225-230.
39. Chiamvimonvat N, Ho CM, Tsai HJ and Hammock BD. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 2007; 50: 225-237.
40. Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD and Wang MH. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol 2007; 293: F342-349.
41. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR and Alkayed NJ. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 2007; 27: 1931-1940.
42. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP and Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 2005; 102: 9772-9777.
43. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ and Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 2005; 102: 2186-2191.
44. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM and Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15: 1244-1253.
45. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC and Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenasederived eicosanoids. Science 1999; 285: 1276-1279.
46. Fleming I. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends Pharmacol Sci 2007; 28: 448-452.
47. Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH and Hammock BD. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 2006; 79: 2311-2319.
48. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD and Shyy JY. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 2005; 102: 16747-16752.
49. Ward JE and Tan X. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. PPAR Res 2007; 2007: 14983.
50. Stienstra R, Duval C, Muller M and Kersten S. PPARs, Obesity, and Inflammation. PPAR Res 2007; 2007: 95974.
51. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M and Desreumaux P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55: 1341-1349.
52. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M and Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327.
53. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H and Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779-18789.
54. Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP and Plat J. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol 2007; 27: 275-283.
55. McAlpine CA, Barak Y, Matise I and Cormier RT. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int J Cancer 2006; 119: 2339-2346.
56. Ponferrada A, Caso JR, Alou L, Colon A, Sevillano D, Moro MA, Lizasoain I, Menchen P, Gomez-Lus ML, Lorenzo P, Cos E, Leza JC and Menchen L. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 2007; 132: 1791-1803.
57. Kohno H, Suzuki R, Sugie S and Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005; 5: 46.
58. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP and Hammock BD. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006; 103: 13646-13651.
59. Morisseau C, Du G, Newman JW and Hammock BD. Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives. Archives of Biochemistry & Biophysics 1998; 356: 214-228.
60. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR and Hammock BD. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A 1999; 96: 8849-8854.
61. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL and Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 2002; 63: 1599-1608.
62. Kim IH, Morisseau C, Watanabe T and Hammock BD. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 2004; 47: 2110-2122.
63. Argiriadi MA, Morisseau C, Goodrow MH, Dowdy DL, Hammock BD and Christianson DW. Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation. J Biol Chem 2000; 275: 15265-15270.
64. Hwang SH, Tsai HJ, Liu JY, Morisseau C and Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007; 50: 3825-3840.
65. Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I and Hammock BD. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido) dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem 2007; 15: 312-323.
66. Wolf NM, Morisseau C, Jones PD, Hock B and Hammock BD. Development of a highthroughput screen for soluble epoxide hydrolase inhibition. Anal Biochem 2006; 355: 71-80.
67. Gomez GA, Morisseau C, Hammock BD and Christianson DW. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci 2006; 15: 58-64.
68. Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ and Hammock BD. Optimization of amidebased inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem 2005; 48: 3621-3629.
69. Kune GA, Kune S and Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Research 1988; 48: 4399-4404.
70. Suh O, Mettlin C and Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-1177.
71. Greenberg ER, Baron JA, Freeman DH, Jr., Mandel JS and Haile R. Reduced risk of largebowel adenomas among aspirin users. The Polyp Prevention Study Group. Journal of the National Cancer Institute 1993; 85: 912-916.
72. Logan RF, Little J, Hawtin PG and Hardcastle JD. Effect of aspirin and non-steroidal antiinflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme.[see comment]. BMJ 1993; 307: 285-289.
73. Martinez ME, McPherson RS, Levin B and Annegers JF. Aspirin and other nonsteroidal antiinflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiology, Biomarkers & Prevention 1995; 4: 703-707.
74. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New England Journal of Medicine 2000; 342: 1946-1952.
75. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, Investigators APCS, Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB and Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas.[see comment]. New England Journal of Medicine 2006; 355: 873-884.
76. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, Pre SAPTI, Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD and Levin B. Celecoxib for the prevention of colorectal adenomatous polyps.[see comment]. New England Journal of Medicine 2006; 355: 885-895.
77. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG, Investigators APT, Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S and Morton DG. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.[see comment]. Gastroenterology 2006; 131: 1674-1682.
78. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx Trial I, Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA and Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.[see comment][erratum appears in N Engl J Med. 2006 Jul 13; 355(2): 221]. New England Journal of Medicine 2005; 352: 1092-1102.
79. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib Study I, Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. [see comment]. New England Journal of Medicine 2005; 352: 1071-1080.